Amphotericin B Colloidal Dispersion for the Treatment of Indian Visceral Leishmaniasis | Zendy

Shyam Sundar | Zendy; H. C. Mehta | Zendy; Amit Chhabra | Zendy; Vishal Singh | Zendy; Vishal Chauhan | Zendy; P. Desjeux | Zendy; Madhukar Rai | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Amphotericin B Colloidal Dispersion for the Treatment of Indian Visceral Leishmaniasis

Author(s) -

Shyam Sundar,

H. C. Mehta,

Amit Chhabra,

Vishal Singh,

Vishal Chauhan,

P. Desjeux,

Madhukar Rai

Publication year - 2006

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/500138

Subject(s) - amphotericin b , medicine , amphotericin b deoxycholate , visceral leishmaniasis , refractory (planetary science) , leishmaniasis , pharmacology , chemotherapy , gastroenterology , immunology , antifungal , dermatology , biology , astrobiology , caspofungin

In Bihar, India, where visceral leishmaniasis (VL) is hyperendemic and refractory to antimony, amphotericin B is the most effective option for the treatment of VL. Lipid formulations of amphotericin B are able to circumvent the toxic effect of conventional amphotericin B, and the total dose of these formulations can be administered over a short duration. However, cost is a major constraint in the use of lipid formulations of amphotericin B. Amphotericin B colloidal dispersion (ABCD), which is a less expensive lipid formulation, has not been tested for the treatment of VL in India.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research